
Shanghai RAAS Blood Products Co Ltd
SZSE:002252

Wall Street
Price Targets
Price Targets Summary
Shanghai RAAS Blood Products Co Ltd
According to Wall Street analysts, the average 1-year price target for
Shanghai RAAS Blood Products Co Ltd
is 7.55 CNY
with a low forecast of 6.87 CNY and a high forecast of 8.4 CNY.
Revenue
Forecast
Revenue Estimate
Shanghai RAAS Blood Products Co Ltd
For the last 8 years the
compound annual growth rate for
Shanghai RAAS Blood Products Co Ltd's revenue is
17%.
The projected
CAGR
for the next 2 years is
9%.
Operating Income
Forecast
Operating Income Estimate
Shanghai RAAS Blood Products Co Ltd
For the last 8 years the
compound annual growth rate for
Shanghai RAAS Blood Products Co Ltd's operating income is
9%.
The projected
CAGR
for the next 3 years is
13%.
Net Income
Forecast
Net Income Estimate
Shanghai RAAS Blood Products Co Ltd
For the last 8 years the
compound annual growth rate for
Shanghai RAAS Blood Products Co Ltd's net income is
4%.
The projected
CAGR
for the next 2 years is
16%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Shanghai RAAS Blood Products Co Ltd's stock price target?
Price Target
7.55
CNY
According to Wall Street analysts, the average 1-year price target for
Shanghai RAAS Blood Products Co Ltd
is 7.55 CNY
with a low forecast of 6.87 CNY and a high forecast of 8.4 CNY.
What is Shanghai RAAS Blood Products Co Ltd's Revenue forecast?
Projected CAGR
9%
For the last 8 years the
compound annual growth rate for
Shanghai RAAS Blood Products Co Ltd's revenue is
17%.
The projected
CAGR
for the next 2 years is
9%.
What is Shanghai RAAS Blood Products Co Ltd's Operating Income forecast?
Projected CAGR
13%
For the last 8 years the
compound annual growth rate for
Shanghai RAAS Blood Products Co Ltd's operating income is
9%.
The projected
CAGR
for the next 3 years is
13%.
What is Shanghai RAAS Blood Products Co Ltd's Net Income forecast?
Projected CAGR
16%
For the last 8 years the
compound annual growth rate for
Shanghai RAAS Blood Products Co Ltd's net income is
4%.
The projected
CAGR
for the next 2 years is
16%.